This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Afternoon. My name is Joel, and I will be your conference operator today. At this time, I would like to welcome everyone to Halazine's third quarter 2026 Financial and Operating Results conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. Please note this event is being recorded. I will now turn the call over to Tron Bui, Halazine's Vice President of Investor Relations. Please go ahead.
Thank you, Operator. Good afternoon and welcome to Halazine's third quarter 2026 Financial and Operating Results Conference Call. In addition to the press release issued today after the market closed, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, HALA's President and Chief Executive Officer, who will provide an update on our business, and Darren Snellgrove, our Chief Financial Officer, who will review our financial results and outlook. On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings patch release and slide presentation. I will now turn the call over to Dr. Helen Torley, and we will start on slide three.
Thank you, Charles, and good afternoon, everyone. I'm pleased to report another exceptionally strong quarter for Halazine, as more patients, physicians, and healthcare systems experience the benefits of subcutaneous delivery with Enhanced. This is reflected in the record total and royalty revenues. And operationally, we continue to demonstrate new growth opportunities resulting from our compounding platform engine, Enhance. In and post the quarter, we significantly expanded the Enhance opportunity with three current partners expanding their agreements to add four new target nominations. Additionally, three Enhance-enabled programs, one each from Pfizer, Insight, and Ergenix, advanced into Phase 1 development. And GSK plans to initiate a Phase 1B study of a subcutaneous formulation of Belantamab with Enhance. With this plan's start, we are on track to achieve 13 Enhance programs in clinical development by year-end. Importantly, we also advanced our two hyperconcentration technologies, Hypercon and AeroCon, the new name for SurfBio, moving these closer to clinical testing. All of this contributed to the record total revenue, royalty revenue and adjusted EBITDA for Q3. Total revenue increased 39% year-over-year to $493 million, driven by royalty revenue, which increased 44% to a record $341 million. These results reflect the continued growth of our established commercial partner product portfolio and the growing contributions from the newer launches, which is resulting in a diversified and growing set of royalty revenue streams. Profitability remained strong during the quarter, with adjusted EBITDA of $336 million and an adjusted EBITDA margin of 68%, reflecting our disciplined executions. Based on this strength, we are raising our full year 2026 financial guidance. Darren will be discussing this in greater detail. Turning to slide four, let me now say a few more words about how we are increasing the enhanced opportunity through expanded agreements and new nominations by current partners. Three current enhanced partners expanded their collaborations and nominated four additional targets. Argenix expanded their agreement to include two additional exclusive targets, bringing the total to eight. INSET expanded and added one additional target to evaluate subcutaneous axolizumab. And in October, Johnson & Johnson added an additional oncology target to its longstanding enhanced collaboration. Collectively, these four new nominations expand the opportunity, further diversify our partners' pipeline, and add new potential sources of milestone and royalty revenues. Let me now move to slide five, and I'll provide some performance highlights on our commercial enhanced portfolio. Darts Lake Subcutaneous, Five Guard High Trillo, and Fezgo have all continued to demonstrate strong royalty revenue growth. In addition to, and on top of this, Okra Vista Novo, of DevoQVantage and Rhybrovent FastPro are adding increasingly meaningful royalty revenues. Enhance provides a competitive advantage for our partners by improving convenience, reducing administration time, and in some cases, improving the safety and tolerability profile compared to the IV treatment. For multiple partner products, these benefits are resulting in strong growth as the SC enables new sites of care and increased access to and for patients. Rhys de Callier, on Ocrevus Novo. Roche noted on their third quarter call that approximately 50% of the Ocrevus Novo starts are patients naive to Ocrevus treatment. This, I believe, demonstrates expansion of Ocrevus Novo into community and more rural treatment settings where IV capacity can be limited. Roche continues to expect high single-digit Ocrevus growth in 2026 and 9 billion Swiss francs or approximately $11 billion in peak franchise sales by 2029. At just over 20% conversion today and with royalty revenues to at least 2034, this represents a large opportunity for Halazan. I'll move now to Bristol-Myers Squibb, an observable humanity. On its third quarter call, BMS reported that approximately 17% of the Opdivo IV business has already converted to Opdivo QVantage, which is the subcutaneous formulation, with uptake occurring across multiple tumor types. Importantly, they also commented that conversion is tracking towards a higher end of its expectation for 30 to 40% of the IV business to ultimately convert to the subcutaneous formulation. SDA Administration, with their hands, is delivering meaningful benefits for patients and physicians, including improved practice efficiency and a more convenient treatment experience. With durable royalties projected for many years and significant conversion ahead, this also represents an attractive growth royalty stream. Johnson & Johnson's Rhypervent Fast Pro is another exciting opportunity. T&J reported 63.5% growth of Rhypervent plus Lecluse in the third quarter, Driven by strong share gains in both first- and second-line lung cancer treatment, continued long-stop take-cross regions, and rapid adoption of the subcutaneous version, Rypervent FastPro. They further noted that they expect FDA approval of Rypervent FastPro in advance head and neck cancer by the end of 2026, which would expand the opportunity beyond lung cancer into another area of significant unmet need. Johnson & Johnson also highlighted that Rappervan is one of their key newer products that is expected to contribute more meaningfully to future growth, and have commented that this growth will be fueled by Rappervan FastPro. This represents another gross royalty revenue stream for Halazine, with royalty revenues projected to the late 2030s. I'll now move to Dargalix Subcutaneous by Garhead, Shulo, and Fezgo. And I'll begin with Dargalix. J&J reported $4.2 billion in sales in the third quarter for Dargolex, reflecting operational growth of 15.6%. Virtually all of the Dargolex-reported sales are for the Dargolex subcutaneous version within hands. This strong performance was driven by continued share gains across all lines of therapy, including 10 points of share gain in the frontline setting, together with ongoing market expansion. With analysts now projecting sales of $21 billion in 2028, we are excited to support the continued growth and expansion of this exceptional product. I'll move now to VibeGuard House Trudeau. Argenix reported total VibeGuard sales of $1.7 billion in the quarter, impressive growth of 54% year-over-year and 13% sequentially. Argenix highlighted continued growth in both generalized myosinic gratis and CIDP, which is driven by the VibeGuard Hetula pre-filled syringe that provides greater patient convenience and flexibility in how treatment is administered. A recent additional driver of growth is the approval for seronegative myosinibrabis, which is already broadening their prescriber base with approximately 10% of seronegative prescribers new to VibeGuard. Further opportunity expansion is projected in 2027 with potential approvals in ocular and pediatric myasthenia gravis. And beyond myasthenia gravis and CIDP, Organics is seeking to expand into a new population of patients, those with immune-mediated necrotizing myositis, or IMNM, with a SPLA planned by year-end. This is a high unmet need patient population for Ergenix as estimated. There are approximately 20,000 patients living with this disease in the United States alone. These opportunities reinforce the potential for 5-Gard Heterologues to continue expanding across indications, patient populations, and prescribers, delivering long-term growth and projected royalty revenues to Halosan into the 2040s. Moving now to Roche's Fesco. In the third quarter, Roche reported that Fesco also continues to deliver strong performance, with global conversion reaching 59%, up 5 percentage points since mid-year, signaling continued strong adoption for a product that was launched six years ago in 2020. The continued conversion from projector reinforces the durability of Fesco, with royalties projected into the 2030s, and the value of a hand in enabling sustained adoption of subcutaneous therapies. Collectively, all six products are demonstrating the continued scalability and durability of Enhance. Our established products continue to deliver strong growth. Our newer launches are becoming increasingly meaningful contributors. And the ongoing clinical, regulatory, and commercial progress are providing multiple drivers for future revenue growth. Moving now to slide six. With the new study starts in the third quarter, we have significantly expanded our product development pipelines. Today, we have 12 enhanced programs in clinical development, three of which the partners have requested to keep confidential at this time. With GSK planning to initiate a Phase 1b study of a subcutaneous formulation of belantamab with enhanced, we are on track to reach 13 clinical-based programs by year-end 2026. Recent advancements to highlight are Pfizer's initiation of a Phase 1 study of Toreconic, their investigational potential first-in-class tri-specific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation. Also, Insight's initiation of a Phase I study evaluating a subcutaneous formulation of their first-in-class antibody designed to selectively target fuchsia calreticulin. And finally, Argenix's evaluation of ARGX119, their first-in-class humanized agonist Monoclonal Antibody, Targeting Musk Importantly, multiple partners are moving programs from collaboration signing into the clinic rapidly within months of signing. This momentum is a strong reflection of a broader trend in biopharmaceutical companies focusing on subcutaneous administration. Subcutaneous delivery is now recognized not simply as a convenience feature, but as an important driver of patient preference, healthcare system efficiency, and Competitive Differentiation, and Market Expansion. This pace of execution, combined with attractive opportunities across oncology, immunologies, and multiple other therapeutic areas, represents a highly attractive set of opportunities for enhanced royalty revenue beginning in the 2029 plus period and extending well into the next decade. This is the compounding platform engine at work. Commercial success driving new partner demand, new agreements creating additional development programs, and those programs building the next wave of potential royalty revenue. An important additional benefit of our compounding platform engine is the continuous innovation that is generated as we work with partners across a growing range of molecules, formulations, and delivery challenges. I am pleased to report that collaboration patents have been obtained by our licensees for seven of the ten launch products. and that collaboration patents are pending for the others. We continue to expect that new collaboration patents will be granted to protect our licensees' innovations as they generate new data from their clinical trials. Let me now move to M-Dase and our modified hyaluronidase IP portfolio. Haloban pioneered and invented the use of hyaluronidases for large-volume subcutaneous delivery. On October 7th, 2026, the Specialized Dutch Patent Court of The Hague rejected Merck's invalidity challenges against Helizine's M-based patent, EP622, and found Keytruda Q-Legs to be infringing the patent. The court also found that there was no reasonable likelihood that EP622 will be declared invalid in the other relevant European member states where EP622 is granted, and that prohibited Mark's European Marketing Approval Holder from committing an infringement in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands by manufacturing or causing to be manufactured, offering, putting on the market, or using to food executives in those countries, or by importing it or holding it in stock for that purpose. Previously, in December of 2025, Helizine won a critical preliminary injunction in Germany for EP622. The Munich Regional Court ordered Merck to halt the launch and distribution of Keytruda Culex in Germany. And in February of 2026, the German Federal Patent Court issued a preliminary opinion in validity proceedings that were brought by Merck, finding that Helizine's EP622 patent is likely valid. Together, these rulings prevent Merck from launching Keytruda Culex in key European markets and prevent Merck from achieving the same adoption and trajectory of Keytruda Culex in Europe as they are doing in the United States. I want to underscore just how important these recent EU court decisions are in supporting the validity of our EP622 patent and supporting Halotham's position as the pioneer and leader for innovating the use of human-derived hyaluronidases for large-volume subcutaneous administration. I'll now move to Hypercon and Ericon, our hyperconcentration technologies. Hypercon and Ericon are complementary technologies to Enhance that extend our leadership in subcutaneous drug delivery, expand our addressable opportunity, and will create additional long-term royalty opportunities for Halosyme. Each has been demonstrated to achieve stable formulations of biologic therapies at a concentration of approximately 500 mg per ml, which is 3-4 fold what is commonly achieved. The resultant lower volume required can allow delivery using a small volume autoinjector at home or in the doctor's office with the potential to further improve the patient treatment experience. To date, five collaboration and licensing agreements have been signed for access to Hypercon, including the potential to use Hypercon with more than 20 potential targets for drugs. We are on track to complete the clinical supply for two partner products formulated with Hypercon in the first quarter of 2027 to support first half 2027 Phase I trial initiations. In parallel, we're advancing the Hypercon formulation for a growing portfolio of development programs, including both commercial-stage and development-stage assets. with several programs originating from recently signed collaborations and others representing future collaboration agreement opportunities. Now a word on Ericon. We're on track with our plans for 2026, which continues to support new deal signings in 2027 and clinical entry in the second half of 2028. With Halozyme's deep expertise, established capabilities, and proven track record in drug delivery, Halozyme is the natural home for innovative drug delivery technologies. I'll now pass the call over to Darren, who will be discussing our financial results, updated outlooks, and capital allocation.
You're reading a preview of the HALO Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing